Market closed

TG Therapeutics/TGTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Ticker

TGTX
Trading on

Industry

Biotechnology

Employees

300

TG Therapeutics Metrics

BasicAdvanced
$3.1B
Market cap
34.16
P/E ratio
$0.64
EPS
2.23
Beta
-
Dividend rate
$3.1B
2.23
$25.38
$6.46
4M
3.581
2.769
62.642
69.947
8.21%
20.47%
87.78%
34.157
9.081
17.64
17.64
46.423
1,341.56%
-150.31%
423.70%
-38.26%

What the Analysts think about TG Therapeutics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.

TG Therapeutics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TG Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy TGTX

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for TG Therapeutics stock?

TG Therapeutics (TGTX) has a market cap of $3.1B as of October 11, 2024.

What is the P/E ratio for TG Therapeutics stock?

The price to earnings (P/E) ratio for TG Therapeutics (TGTX) stock is 34.16 as of October 11, 2024.

Does TG Therapeutics stock pay dividends?

No, TG Therapeutics (TGTX) stock does not pay dividends to its shareholders as of October 11, 2024.

When is the next TG Therapeutics dividend payment date?

TG Therapeutics (TGTX) stock does not pay dividends to its shareholders.

What is the beta indicator for TG Therapeutics?

TG Therapeutics (TGTX) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.